Irbesartan

• CAT Number: A000217
• CAS Number: 138402-11-6
• Molecular Formula: C25H28N6O
• Molecular Weight: 428.50
• Purity: ≥95%
• Synonyms: 138402-11-6; Aprovel; Avapro; Karvea; SR-47436
• Target: Angiotensin Receptor
• Solubility: >17.4mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
• InChI: InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
• InChIKey: YOSHYTLCDANDAN-UHFFFAOYSA-N
• SMILES: CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5

Irbesartan（Cat No.:A000217）is an angiotensin II receptor blocker (ARB) used to treat hypertension and manage kidney disease in patients with type 2 diabetes. It works by blocking the effects of angiotensin II, a hormone that constricts blood vessels, thus helping to lower blood pressure and improve blood flow. Irbesartan is effective in reducing the risk of stroke, heart attack, and progression of diabetic nephropathy. Its once-daily dosing and favorable side effect profile make it a commonly prescribed option for long-term cardiovascular and renal protection.

Reference

1: Suryadevara V, Lankapalli SR, Danda LH, Pendyala V, Katta V. Studies on
jackfruit seed starch as a novel natural superdisintegrant for the design and
evaluation of irbesartan fast dissolving tablets. Integr Med Res. 2017
Sep;6(3):280-291. doi: 10.1016/j.imr.2017.04.001. Epub 2017 May 26. PubMed PMID:
28951842; PubMed Central PMCID: PMC5605381.

2: Yamabe H, Kaikita K, Matsumura T, Iwasa A, Koyama J, Uemura T, Morikami Y,
Tsunoda R, Morihisa K, Fujimoto K, Kajiwara I, Matsui K, Tsujita K, Ogawa H.
Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto:
Atrial Fibrillation Suppression Trial (SILK study). J Cardiol. 2017 Sep 5. pii:
S0914-5087(17)30210-1. doi: 10.1016/j.jjcc.2017.07.010. [Epub ahead of print]
PubMed PMID: 28886992.

3: Zhou T, Huang X, Cai X, Xie L. Combined treatment of irbesartan and diltiazem
ameliorates endothelium dependent vasodilatation in hypertensives. Clin Exp
Hypertens. 2017;39(7):612-618. doi: 10.1080/10641963.2017.1306537. Epub 2017 Jun
14. PubMed PMID: 28613098.

4: Omboni S, Malacco E, Napoli C, Modesti PA, Manolis A, Parati G, Agabiti-Rosei
E, Borghi C. Erratum to: Efficacy of Zofenopril vs. Irbesartan in Combination
with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not
Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized
/Z/ Studies. Adv Ther. 2017 Jun;34(6):1498-1499. doi: 10.1007/s12325-017-0537-4.
PubMed PMID: 28452039; PubMed Central PMCID: PMC5487858.

5: Ye XL, Huang WC, Zheng YT, Liang Y, Gong WQ, Yang CM, Liu B. [Irbesartan
ameliorates cardiac inflammation in type 2 diabetic db/db mice]. Nan Fang Yi Ke
Da Xue Xue Bao. 2016 Apr 20;37(4):505-511. Chinese. PubMed PMID: 28446404.

6: Anusha A, Narendar D, Krishna Murthy B, Goverdhan P. Influence of Single and
Multi Dose Treatment of Glipizide on Pharmacokinetics and Pharmacodynamics of
Irbesartan in Normal and Hypertensive Rats. High Blood Press Cardiovasc Prev.
2017 Jun;24(2):179-185. doi: 10.1007/s40292-017-0195-2. Epub 2017 Apr 6. PubMed
PMID: 28386752.

7: Li S, Wang K, Xu G, Ji J, Qin C. The intervention effect of zinc
supplementation on irbesartan treatment for atherosclerosis of ApoE-/- mice. Pak
J Pharm Sci. 2016 Nov;29(6):1907-1912. PubMed PMID: 28375105.

8: Liossi ΑS, Ntountaniotis D, Kellici TF, Chatziathanasiadou MV, Megariotis G,
Mania M, Becker-Baldus J, Kriechbaum M, Krajnc A, Christodoulou E, Glaubitz C,
Rappolt M, Amenitsch H, Mali G, Theodorou DN, Valsami G, Pitsikalis M, Iatrou H,
Tzakos AG, Mavromoustakos T. Exploring the interactions of irbesartan and
irbesartan-2-hydroxypropyl-β-cyclodextrin complex with model membranes. Biochim
Biophys Acta. 2017 Jun;1859(6):1089-1098. doi: 10.1016/j.bbamem.2017.03.003. Epub
2017 Mar 6. PubMed PMID: 28274845.

9: Omboni S, Malacco E, Napoli C, Modesti PA, Manolis A, Parati G, Agabiti-Rosei
E, Borghi C. Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide
Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a
Previous Monotherapy: A Review of the Double-Blind, Randomized /Z/ Studies. Adv
Ther. 2017 Apr;34(4):784-798. doi: 10.1007/s12325-017-0497-8. Epub 2017 Mar 4.
Review. Erratum in: Adv Ther. 2017 Apr 27;:. Adv Ther. 2017 Jun;34(6):1498-1499.
PubMed PMID: 28260186; PubMed Central PMCID: PMC5406448.

10: Yousif NG, Hadi NR, Al-Amran F, Zigam QA. Cardioprotective effects of
irbesartan in polymicrobial sepsis : The role of the p38MAPK/NF-κB signaling
pathway. Herz. 2017 Jan 31. doi: 10.1007/s00059-017-4537-6. [Epub ahead of print]
PubMed PMID: 28144715.